There are several trials using combinations of immunotherapy to increase the survival of patients with urothelial carcinoma. For example, there is a trial investigating monotherapy immunotherapy versus immunotherapy with an IDO inhibitor, explains Bellmunt.

The combination of nivolumab (Opdivo) and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced urothelial carcinoma in an early-phase clinical trial. The dual immunotherapy regimen resulted in an objective response rate (ORR) of 32.0% (95% CI, 14.9%-53.5%) among 25 evaluable patients. The disease control rate, which consists of ORR and stable disease, was 44.0% (95% CI, 24.4%-65.1%) in the patients with urothelial carcinoma.

According to Bellmunt, this combination is moving to a randomized phase III trial in the first- and second-line setting, particularly for patients who cannot receive chemotherapy.

There are several trials using combinations of immunotherapy to increase the survival of patients with urothelial carcinoma. For example, there is a trial investigating monotherapy immunotherapy versus immunotherapy with an IDO inhibitor, explains Bellmunt.

The combination of nivolumab (Opdivo) and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced urothelial carcinoma in an early-phase clinical trial. The dual immunotherapy regimen resulted in an objective response rate (ORR) of 32.0% (95% CI, 14.9%-53.5%) among 25 evaluable patients. The disease control rate, which consists of ORR and stable disease, was 44.0% (95% CI, 24.4%-65.1%) in the patients with urothelial carcinoma.

According to Bellmunt, this combination is moving to a randomized phase III trial in the first- and second-line setting, particularly for patients who cannot receive chemotherapy.